Junshi Biosciences Announces Co-Development Agreement with IMCAS to Advance Neutralizing Antibodies as Potential Novel Treatment for COVID-19

NEXT STORY
Itamar™ Medical Implements Broad Range of Actions in Response to COVID-19 Pandemic
PREV STORY
Emergency Covid-19 Response Plans in Place Throughout Barrick
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Merus kündigt Präsentation der klinischen Daten der Phase I für MCLA-158 auf dem „2021 Gastrointestinal Cancers Symposium“ der American Society of Clinical Oncology (ASCO) an

author_avatar
NASDAQ Market News

GSK and Vir Biotechnology Expand Coronavirus Collaboration to Advance New Therapeutics for Influenza and Other Respiratory Viruses

author_avatar
NASDAQ Market News

Largest Real-World Registry Supporting Neovasc Reducer™ Safety and Efficacy Outcomes Published in International Journal of Cardiology

author_avatar
NASDAQ Market News